Joseph Oliveto Sells 43,000 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 43,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $2.25, for a total transaction of $96,750.00. Following the completion of the sale, the chief executive officer directly owned 303,721 shares of the company’s stock, valued at $683,372.25. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Joseph Oliveto also recently made the following trade(s):

• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.25, for a total value of $1,125.00.

Milestone Pharmaceuticals Stock Performance

MIST stock traded down $0.15 during trading on Friday, hitting $2.04. The company had a trading volume of 6,348,983 shares, compared to its average volume of 3,926,556. The firm has a 50-day moving average price of $2.22 and a 200-day moving average price of $1.96. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. The firm has a market cap of $173.74 million, a PE ratio of -2.49 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a 1-year low of $0.63 and a 1-year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. On average, analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Analyst Ratings Changes

MIST has been the subject of a number of analyst reports. Wells Fargo & Company upped their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a report on Tuesday. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Finally, Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Milestone Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently bought and sold shares of MIST. Propel Bio Management LLC raised its holdings in Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after purchasing an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC purchased a new position in shares of Milestone Pharmaceuticals in the third quarter valued at $6,444,000. Simplify Asset Management Inc. raised its stake in shares of Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after buying an additional 1,842,974 shares during the last quarter. Pathstone Holdings LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $2,000,000. Finally, Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $1,333,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.